[go: up one dir, main page]

MX9605650A - Formulaciones de propionato de fluticasona. - Google Patents

Formulaciones de propionato de fluticasona.

Info

Publication number
MX9605650A
MX9605650A MX9605650A MX9605650A MX9605650A MX 9605650 A MX9605650 A MX 9605650A MX 9605650 A MX9605650 A MX 9605650A MX 9605650 A MX9605650 A MX 9605650A MX 9605650 A MX9605650 A MX 9605650A
Authority
MX
Mexico
Prior art keywords
fluticasone propionate
formulations
inhalation
formulation
relates
Prior art date
Application number
MX9605650A
Other languages
English (en)
Inventor
David Alexander Tainsh
Trevor Leslie Ilott
Dorothy Jill Snell
Li Fong Lam
Original Assignee
Glaxo Wellcome Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Australia Ltd filed Critical Glaxo Wellcome Australia Ltd
Publication of MX9605650A publication Critical patent/MX9605650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se relaciona con formulaciones que pueden usarse para la administracion de medicamentos por inhalacion. En particular, la invencion se relaciona con una formulacion que comprende propionato de fluticasona que tiene sustancialmente en su totalidad un tamaño de partícula de menos de 12 micrones, uno o más tensoactivos, uno o más agentes amortiguadores y agua. También se describe un método para tratar padecimientos respiratorios, el cual comprende administrar por inhalacion una cantidad efectiva de una formulacion como la definida.
MX9605650A 1994-05-21 1995-05-19 Formulaciones de propionato de fluticasona. MX9605650A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
PCT/EP1995/001913 WO1995031964A1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations

Publications (1)

Publication Number Publication Date
MX9605650A true MX9605650A (es) 1998-05-31

Family

ID=10755515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605650A MX9605650A (es) 1994-05-21 1995-05-19 Formulaciones de propionato de fluticasona.

Country Status (28)

Country Link
US (1) US5993781A (es)
EP (1) EP0760649B1 (es)
JP (1) JPH10500420A (es)
KR (2) KR970703132A (es)
CN (1) CN1098680C (es)
AT (1) ATE207734T1 (es)
AU (1) AU710821B2 (es)
BR (1) BR9507746A (es)
CA (1) CA2190763A1 (es)
CY (1) CY2294B1 (es)
CZ (1) CZ285966B6 (es)
DE (1) DE69523587T2 (es)
DK (1) DK0760649T3 (es)
ES (1) ES2164767T3 (es)
FI (1) FI118512B (es)
GB (1) GB9410222D0 (es)
HU (1) HU223316B1 (es)
IL (1) IL113794A (es)
MX (1) MX9605650A (es)
NO (1) NO313785B1 (es)
NZ (1) NZ287425A (es)
PL (1) PL180318B1 (es)
PT (1) PT760649E (es)
RU (1) RU2161485C2 (es)
SI (1) SI0760649T1 (es)
TW (1) TW438604B (es)
WO (1) WO1995031964A1 (es)
ZA (1) ZA954101B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ATE416184T1 (de) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
DK1476201T3 (da) 2002-02-19 2009-03-30 Resolution Chemicals Ltd Solvent-baseret sterilisering af steroider
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
WO2004105809A1 (en) * 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US7892483B2 (en) 2004-03-12 2011-02-22 Cipla Limited Sterilization process
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2013169647A1 (en) 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102379309B1 (ko) 2014-09-15 2022-03-28 베로나 파마 피엘씨 Ｒｐｌ５５４를 포함하는 액상 흡입제
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DK0616524T3 (da) * 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
RU2135183C1 (ru) * 1996-02-29 1999-08-27 Государственный научно-клинический центр охраны здоровья шахтеров Способ лечения гормонозависимой бронхиальной астмы

Also Published As

Publication number Publication date
PT760649E (pt) 2002-04-29
CY2294B1 (en) 2003-07-04
KR100361413B1 (ko) 2003-02-19
NO964938D0 (no) 1996-11-20
CZ285966B6 (cs) 1999-12-15
CZ342396A3 (en) 1997-07-16
RU2161485C2 (ru) 2001-01-10
KR970703132A (ko) 1997-07-03
HU9603227D0 (en) 1997-01-28
CA2190763A1 (en) 1995-11-30
AU2614595A (en) 1995-12-18
IL113794A0 (en) 1995-08-31
FI964634A0 (fi) 1996-11-20
WO1995031964A1 (en) 1995-11-30
NO313785B1 (no) 2002-12-02
PL317225A1 (en) 1997-03-17
TW438604B (en) 2001-06-07
GB9410222D0 (en) 1994-07-06
HK1004192A1 (en) 1998-11-20
DK0760649T3 (da) 2002-01-28
ZA954101B (en) 1996-01-29
IL113794A (en) 2000-10-31
DE69523587T2 (de) 2002-06-27
HU223316B1 (hu) 2004-05-28
SI0760649T1 (en) 2002-04-30
NZ287425A (en) 1998-05-27
AU710821B2 (en) 1999-09-30
EP0760649A1 (en) 1997-03-12
CN1098680C (zh) 2003-01-15
US5993781A (en) 1999-11-30
EP0760649B1 (en) 2001-10-31
BR9507746A (pt) 1997-08-19
ES2164767T3 (es) 2002-03-01
FI118512B (fi) 2007-12-14
NO964938L (no) 1996-11-20
KR970703130A (ko) 1997-07-03
CN1148804A (zh) 1997-04-30
FI964634L (fi) 1996-11-20
JPH10500420A (ja) 1998-01-13
PL180318B1 (pl) 2001-01-31
ATE207734T1 (de) 2001-11-15
DE69523587D1 (de) 2001-12-06
HUT76552A (en) 1997-09-29

Similar Documents

Publication Publication Date Title
MX9605650A (es) Formulaciones de propionato de fluticasona.
CA2125665A1 (en) Medicaments
GB9426252D0 (en) Pharmaceutical composition
MY108748A (en) Medicaments
ES2133130A1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
GB9425160D0 (en) Medicaments
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
ATE203902T1 (de) Fluorchlorkohlenwasserstofffreie aerosolformulierungen
SE9604486D0 (sv) Novel formulation
IL101056A (en) Composition for nasal treatment
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
EP0744176A3 (en) Methods for inhibiting bone loss
TR199600888A1 (xx) İlaçlar.